Anti-VEGF compounds in the treatment of neovascular age related macular degeneration.
about
Concise Review: Patient-Specific Stem Cells to Interrogate Inherited Eye DiseaseThe REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndromeAnti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical applicationHyperglycaemia exacerbates choroidal neovascularisation in mice via the oxidative stress-induced activation of STAT3 signalling in RPE cellsEffect of intravitreal injection of ranibizumab on retinal ganglion cells and microvessels in the early stage of diabetic retinopathy in rats with streptozotocin-induced diabetesγ-Secretase inhibition of murine choroidal neovascularization is associated with reduction of superoxide and proinflammatory cytokines.Sterculic acid antagonizes 7-ketocholesterol-mediated inflammation and inhibits choroidal neovascularization.Complement regulatory protein CD46 protects against choroidal neovascularization in mice.7-Ketocholesterol induces inflammation and angiogenesis in vivo: a novel rat model.Age-dependent changes in FasL (CD95L) modulate macrophage function in a model of age-related macular degenerationOptical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis)TCCR/WSX-1 is a novel angiogenic factor in age-related macular degeneration.Comparison of Mouse and Human Retinal Pigment Epithelium Gene Expression Profiles: Potential Implications for Age-Related Macular Degeneration.Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processesIn vivo bioluminescence imaging of hyperglycemia exacerbating stem cells on choroidal neovascularization in miceThe physiological impact of microRNA gene regulation in the retina.Therapeutic potential of a monoclonal antibody blocking the Wnt pathway in diabetic retinopathyHypomethylation of the IL17RC promoter associates with age-related macular degeneration.Vascular endothelial growth factor A polymorphisms and age-related macular degeneration: a systematic review and meta-analysisGene therapy strategies in glaucoma and application for steroid-induced hypertensionAntiangiogenic activity and pharmacogenomics of medicinal plants from traditional korean medicine.Genetic and Epigenetic Regulation in Age-related Macular Degeneration.Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration.Emerging biotechnological strategies for non-viral antiangiogenic gene therapy.Cerebrovascular remodeling and epilepsyWhy and how to target angiogenesis in focal epilepsies.Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases.Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy.Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications.The Efficacy and Safety of Current Treatments in Diabetic Macular Edema: A Systematic Review and Network Meta-Analysis.Synergic effects of VEGF-A and SDF-1 on the angiogenic properties of endothelial progenitor cells.Omega-3 polyunsaturated fatty acids reduce vascular endothelial growth factor production and suppress endothelial wound repair.The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model.Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model.An anti-angiogenic reverse thermal gel as a drug-delivery system for age-related wet macular degeneration.A case of idiopathic choroidal neovascular membrane in a young patient.Extract of Litsea japonica ameliorates blood-retinal barrier breakdown in db/db mice.EGHB010, a Standardized Extract of Paeoniae Radix and Glycyrrhizae Radix, Inhibits VEGF-Induced Tube Formation In Vitro and Retinal Vascular Leakage and Choroidal Neovascularization In Vivo.Toll-like receptor 3 activation in retinal pigment epithelium cells - Mitogen-activated protein kinase pathways of cell death and vascular endothelial growth factor secretion.Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review.
P2860
Q26774786-AF98F168-D8CF-43B3-92EC-27B3BF70B921Q27000201-99235308-688B-4C2A-A792-1E18BDE601ACQ28082140-E17B9379-B847-4CB6-BF2E-7944087DE1ACQ28484492-D1D9D376-31D9-47EA-A0C5-6C9431EF3BECQ33744652-ECE952DC-F887-4BDA-9E38-F41F8BD79040Q34113394-D2E68EBF-1513-4479-A584-B5EAB254B670Q34161139-06C2D5C9-78EE-44F8-BE70-60FABF62204AQ34299745-A19589C6-06B0-4CA3-A6A4-6DCF271197FEQ34586643-67858B5D-633C-4A6E-B119-6C7AC5B99BA2Q34791186-267B7E59-F8C2-4A95-A760-0873592A8D62Q35016867-D6960892-0AA2-4402-B44E-EAA66D132240Q35736348-0465116D-CB6A-475D-91A8-FE92B9D7EF75Q35827351-431941BD-229A-4629-B78C-C4D768076A0DQ35858012-07EBC03A-2CF9-4A41-831C-5E80CDF0343BQ36013023-A0E68346-0463-4B10-8EE3-AFA182D018DDQ36238203-8C4AD7F9-C32D-47A1-8727-F0FC3C62AE31Q36339514-9A18501A-838B-46FC-9951-D64A5461DFA3Q36442673-458FE396-C1F1-4B93-A8EC-A301E50ED93BQ36908876-D9AED468-DEB0-41F7-8477-30EA50306B7AQ37060277-E928F08E-3E3A-4CD7-A70C-D5FBBF9901FCQ37077910-0A665365-2578-41A4-9D6D-C4D778DDDB33Q37127362-E6EAA603-BB61-4147-BCFE-7311374F15AAQ38032311-26339779-1EF8-4590-9547-C2D903A6C88CQ38034448-E15E0A4F-619B-489B-9DBB-258956C62785Q38052687-A111BDA1-F3DD-4396-8CD6-9ABA4A7C8282Q38058377-88878106-2DBF-4423-B74D-D4E302ACB73FQ38108833-15D1B7E0-9A42-400B-BF14-78E1E53F9946Q38128390-B44433F4-B33B-417E-BB4D-7B8E28BF4DD6Q38818237-5D28E90F-4D71-4B87-AEF2-DF1672DA4C7BQ38902223-1918D53D-4E41-45F6-A998-78D11837F624Q39108577-1F7F425B-13D8-45FB-B813-9B3EDB4CFB11Q39275466-EAB3C254-1B27-49F7-B076-B15A3DA90D4CQ40002867-72AAA830-328E-4B02-90CB-78C3E310E715Q40023737-27704D63-7833-461C-92E6-25A676BE922BQ41970943-D1D6C66A-9BED-413D-BC1B-30CDB38A5DBBQ43100454-446BE810-971E-43F6-9602-344D1B12ABA1Q44418091-5806C315-36CC-408D-BEB7-5B08F58FE5AEQ47758215-1F308CA5-64E5-43EC-8656-BDFD36479169Q50237265-5997C5E9-46E0-4637-A765-E55D8637AC7DQ52632539-1BB8653A-2372-4216-9FA7-8C55445D41E7
P2860
Anti-VEGF compounds in the treatment of neovascular age related macular degeneration.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-VEGF compounds in the treatment of neovascular age related macular degeneration.
@en
Anti-VEGF compounds in the treatment of neovascular age related macular degeneration.
@nl
type
label
Anti-VEGF compounds in the treatment of neovascular age related macular degeneration.
@en
Anti-VEGF compounds in the treatment of neovascular age related macular degeneration.
@nl
prefLabel
Anti-VEGF compounds in the treatment of neovascular age related macular degeneration.
@en
Anti-VEGF compounds in the treatment of neovascular age related macular degeneration.
@nl
P1433
P1476
Anti-VEGF compounds in the treatment of neovascular age related macular degeneration.
@en
P2093
P304
P356
10.2174/138945011794182674
P577
2011-02-01T00:00:00Z